Lipidor AB on the home stretch - exciting week ahead

Lipidor AB has this morning announced database lock in its phase III clinical study of AKP02G2 for treatment of psoriasis.
This means that we can expect the result of the study within 7 - 14 days from now, and as it is "make it or brake it" for Lipidor, it is extraordinary exciting. At LSIF, we remain optimistic given the fact, that the reasons for just marginally failing the previous study are well known and has been dealt with, but there is always a process risk.

Read their announcement here.